Call comes after European Medicines Agency reaffirms benefits outweigh very small risk of blood clots
Brussels has encouraged EU member states to act on a new European Medicines Agency opinion that the benefits of the Oxford/AstraZeneca Covid vaccine outweigh the risks of blood clots in all adult age groups.
The European commissioner for health, Stella Kyriakides, emphasised the vaccine’s importance as part of the EU’s strategy despite months of controversy following the latest conclusions from the EMA.
